Company Description
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine.
The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables focusing on the single cell and spatial analysis markets.
Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California. As of February 21, 2025, Singular Genomics Systems, Inc. was taken private.
| Country | United States |
| Founded | 2016 |
| IPO Date | May 27, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 255 |
| CEO | Andrew Spaventa |
Contact Details
Address: 3010 Science Park Road San Diego, California 92121 United States | |
| Phone | 858 333 7830 |
| Website | singulargenomics.com |
Stock Details
| Ticker Symbol | OMIC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $22.00 |
| CIK Code | 0001850906 |
| CUSIP Number | 82933R100 |
| ISIN Number | US82933R1005 |
| Employer ID | 81-2948451 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Andrew Spaventa | Founder, Chief Executive Officer, President and Chairperson of the Board |
| Dr. David L. Barker Ph.D. | Founder, Member of Scientific Advisory Board and Independent Director |
| Dr. Eli N. Glezer Ph.D. | Founder, Chief Scientific Officer and Chair of Scientific Advisory Board |
| Dalen Meeter | Chief Financial Officer |
| Dr. Jyotsna Ghai Ph.D. | Chief Operating Officer |
| Eric Stier | Senior Vice President, General Counsel and Secretary |
| Vincent Brancaccio | Head of Human Resources |
| Jorge Velarde Jr., MBA | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 21, 2025 | EFFECT | Notice of Effectiveness |
| Feb 21, 2025 | 25-NSE | Filing |
| Feb 21, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 21, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 21, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 21, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 21, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 21, 2025 | POS AM | Post-Effective amendments for registration statement |
| Feb 19, 2025 | 8-K | Current Report |
| Feb 13, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |